Your browser doesn't support javascript.
loading
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn, Lindsay B; Khuong-Quang, Dong-Anh; Hansford, Jordan R; Landi, Daniel; van der Lugt, Jasper; Leary, Sarah E S; Driever, Pablo Hernáiz; Bailey, Simon; Perreault, Sébastien; McCowage, Geoffrey; Waanders, Angela J; Ziegler, David S; Witt, Olaf; Baxter, Patricia A; Kang, Hyoung Jin; Hassall, Timothy E; Han, Jung Woo; Hargrave, Darren; Franson, Andrea T; Yalon Oren, Michal; Toledano, Helen; Larouche, Valérie; Kline, Cassie; Abdelbaki, Mohamed S; Jabado, Nada; Gottardo, Nicholas G; Gerber, Nicolas U; Whipple, Nicholas S; Segal, Devorah; Chi, Susan N; Oren, Liat; Tan, Enrica E K; Mueller, Sabine; Cornelio, Izzy; McLeod, Lisa; Zhao, Xin; Walter, Ashley; Da Costa, Daniel; Manley, Peter; Blackman, Samuel C; Packer, Roger J; Nysom, Karsten.
Afiliação
  • Kilburn LB; Children's National Hospital, Washington, DC, USA. lkilburn@childrensnational.org.
  • Khuong-Quang DA; Children's Cancer Centre, Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Hansford JR; Michael Rice Centre for Hematology and Oncology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Landi D; South Australia Health and Medical Research Institute, Adelaide, Australia; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, South Australia, Australia.
  • van der Lugt J; Duke University, Durham, NC, USA.
  • Leary SES; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Driever PH; Cancer and Blood Disorders Center, Seattle Children's, Seattle, WA, USA.
  • Bailey S; Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Berlin, German HIT-LOGGIC-Registry for LGG in Children and Adolescents, Berlin, Germany.
  • Perreault S; Great North Children's Hospital and Newcastle University Centre for Cancer, Newcastle-upon-Tyne, UK.
  • McCowage G; CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada.
  • Waanders AJ; Sydney Children's Hospitals Network, Westmead, New South Wales, Australia.
  • Ziegler DS; Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
  • Witt O; Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
  • Baxter PA; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia.
  • Kang HJ; School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
  • Hassall TE; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Han JW; Clinical Cooperation Unit, Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hargrave D; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
  • Franson AT; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Yalon Oren M; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Toledano H; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
  • Larouche V; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, Republic of Korea.
  • Kline C; Children's Health Queensland Hospital and Health Service, South Brisbane, QLD, Australia.
  • Abdelbaki MS; Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
  • Jabado N; UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children, London, UK.
  • Gottardo NG; C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Gerber NU; Pediatric Hemato-Oncology, Sheba Medical Center, Ramat Gan, Israel.
  • Whipple NS; Department of Pediatric Oncology, Schneider Children's Medical Center, Petach Tikva, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Segal D; Department of Pediatrics, Centre Mère-Enfant Soleil du CHU de Québec-Université Laval, Quebec City, Quebec, Canada.
  • Chi SN; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Oren L; Division of Hematology and Oncology, Department of Pediatrics, School of Medicine, Washington University, St. Louis, MO, USA.
  • Tan EEK; McGill University Health Centre (MUHC), Montreal Children's Hospital (MCH), Montreal, Quebec, Canada.
  • Mueller S; Department of Pediatric and Adolescent Oncology and Hematology, Perth Children's Hospital, Perth, Australia, and Brain Tumor Research Program, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
  • Cornelio I; Department of Oncology, University Children's Hospital, Zurich, Switzerland.
  • McLeod L; Primary Children's Hospital and University of Utah, Salt Lake City, UT, USA.
  • Zhao X; NYU Langone Health, New York, NY, USA.
  • Walter A; Pediatric Neuro-Oncology, Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
  • Da Costa D; Department of Hematology & Oncology, Rambam Healthcare Campus, Haifa, Israel.
  • Manley P; Haematology/Oncology Service, KK Women's and Children's Hospital, Singapore, Singapore.
  • Blackman SC; Department of Neurology, Neurosurgery and Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
  • Packer RJ; Day One Biopharmaceuticals, Brisbane, CA, USA.
  • Nysom K; Day One Biopharmaceuticals, Brisbane, CA, USA.
Nat Med ; 30(5): 1500, 2024 May.
Article em En | MEDLINE | ID: mdl-38467878

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article